OfficeHours

AUGUST 9, 2023

Once improved, the exit can then take place, usually in the form of another sale or an Initial Public Offering (IPO), both of which are usually under the advice of an investment bank. You must be able to consider long-term goals, assess risk, and craft plans to enhance the value of portfolio companies.

Private Equity 130

Private Equity Equities Investment Banking Investment 130

Focus Investment Banking

JANUARY 3, 2024

FAT Brands bought Smokey Bones for $30 million, which adds the first barbeque brand to FAT’s growing portfolio. Cava opened the IPO window and showed that a good company can go public in any market. Subway sold to Roark Capital for $9.6 The partnership enables Smokey Bones to grow via FAT’s aggressive franchising strategy as well.

Acquisitions 52

Acquisitions M&A Portfolio Valuation 52

Cooley M&A

SEPTEMBER 16, 2022

There are compelling rationales for adopting a dual-class structure, but even proponents of the structure generally acknowledge that these benefits are significantly mitigated once the dual-class shares are out of the hands of the founders and/or pre-IPO stockholders. Potential carve outs for M&A voting agreements. Stockholder litigation.

M&A 59

M&A IPO Shares Mergers and Acquisitions 59

Sun Acquisitions

SEPTEMBER 16, 2024

A diversified revenue portfolio strengthens your business’s resilience and makes it more attractive to a broader range of buyers. Common exit strategies include selling to strategic buyers, private equity firms, management buyouts (MBOs), or going public through an initial public offering (IPO).

Negotiation 59

Negotiation Business Sale Management 59

Focus Investment Banking

APRIL 14, 2024

Many smaller operators who are well positioned with a solid customer base, a robust portfolio of goods, and healthier product lines could explore a sale at today’s attractive pricing, with options to sell to an industry competitor or a private equity group (PEG). Bakery industry challenges remain, and the market is increasingly competitive.

M&A 52

M&A Food Private Equity Manufacturing 52

Cooley M&A

JANUARY 23, 2024

Strained access to public markets and funding The IPO market remained relatively inactive in 2023, leading many life sciences companies looking to raise funds to turn to other exit strategies. Additional major acquisitions of 2023 included Pfizer’s acquisition of Seagen for $43 billion and Merck’s acquisition of Prometheus for $10.8

M&A 52

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 52

Cooley M&A

FEBRUARY 1, 2024

Private equity slowed but not stopped by financing environment Despite record amounts of dry powder accumulating for sponsors, high financing costs, persistent valuation gaps and a closed tech IPO market led to a significant decrease in private equity M&A activity in 2023. Despite some isolated bright spots – such as Thoma Bravo’s $10.7

M&A 59

M&A Mergers and Acquisitions Private Equity Equities 59

Cooley M&A

JANUARY 22, 2021

Fortunately, in May 2020, the SEC adopted amendments to the financial disclosure requirements that alleviated some of the burden for public company buyers in those transactions by permitting the use of abbreviated financial statements without the need to seek exemptive relief, as discussed in more detail in our previous blog post.

M&A 40

M&A Mergers and Acquisitions Collaboration Mergers 40

Cooley M&A

JANUARY 25, 2023

Similarly, we expect sponsors to actively pursue carve out opportunities – like Francisco Partners’ carve out acquisition of the data and analytics assets from IBM’s Watson Health business – in 2023 as tech giants streamline their portfolios to focus on their core businesses.

M&A 52

M&A Mergers and Acquisitions Private Equity Mergers 52

Focus Investment Banking

NOVEMBER 18, 2024

Public Markets: It is possible that a few of the car wash platforms with strong growth and financial performance pursue an initial public offering (IPO). A strong car wash IPO could potentially overcome the investor skepticism created by Mister Car Wash and Driven Brands and open the door for a few other platforms to follow suit.

Private Equity 52

Private Equity Equities IPO Valuation 52

Focus Investment Banking

FEBRUARY 11, 2025

Overcoming Marketplace Uncertainty Rising interest rates introduced a difficult environment for private equity recapitalizations (where private equity groups sell a portfolio company to another buyer), so few of the older PE-backed ophthalmology organizations traded hands over the last few years.

Private Equity 52

Private Equity Healthcare Equities Medical 52

Cooley M&A

JANUARY 22, 2025

Portfolio optimization through divestitures of noncore assets In addition to pharmas smaller appetite in 2024, pharma companies continued to slim down by shedding nonessential assets to sharpen their strategic focus on core products.

M&A 64

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 64

Cooley M&A

FEBRUARY 15, 2017

Over the next few days, we will run a series of Cooley M&A blog posts with some brief observations that offer some M&A highlights over the past year and our thoughts for the year to come. We are seeing funds increasingly fundraising for tech plays and are acquiring the needed sector expertise to build their tech portfolios.

M&A 40

M&A IPO Pharmaceutical Valuation 40